Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2

McBride, Christopher; Cheruvallath, Zacharia; Komandla, Mallareddy; Tang, Mingnam; Farrell, Pamela; Lawson, J. David; Vanderpool, Darin; Wu, Yiqin; Dougan, Douglas R.; Plonowski, Artur; Holub, Corine; Larson, Chris

doi:10.1016/j.bmcl.2016.04.072

Title: Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2

Authors:

McBride, Christopher; Cheruvallath, Zacharia; Komandla, Mallareddy; Tang, Mingnam; Farrell, Pamela; Lawson, J. David; Vanderpool, Darin; Wu, Yiqin; Dougan, Douglas R.; Plonowski, Artur;

; Larson, Chris

Publication Date:: 2016-06-01

Sponsoring Org.:: USDOE Office of Science (SC), Basic Energy Sciences (BES)

OSTI Identifier:: 1358849

Grant/Contract Number:: AC02-05CH11231

Resource Type:: Publisher's Accepted Manuscript

Journal Name:: Bioorganic and Medicinal Chemistry Letters

Additional Journal Information:: Journal Name: Bioorganic and Medicinal Chemistry Letters Journal Volume: 26 Journal Issue: 12; Journal ID: ISSN 0960-894X

Publisher:: Elsevier

Country of Publication:: United Kingdom

Language:: English

Citation Formats


                    McBride, Christopher, Cheruvallath, Zacharia, Komandla, Mallareddy, Tang, Mingnam, Farrell, Pamela, Lawson, J. David, Vanderpool, Darin, Wu, Yiqin, Dougan, Douglas R., Plonowski, Artur, Holub, Corine, and Larson, Chris. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2.  United Kingdom: N. p., 2016. 
Web.  doi:10.1016/j.bmcl.2016.04.072.

Copy to clipboard


                    McBride, Christopher, Cheruvallath, Zacharia, Komandla, Mallareddy, Tang, Mingnam, Farrell, Pamela, Lawson, J. David, Vanderpool, Darin, Wu, Yiqin, Dougan, Douglas R., Plonowski, Artur, Holub, Corine, & Larson, Chris. Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2.  United Kingdom.  https://doi.org/10.1016/j.bmcl.2016.04.072

Copy to clipboard


                    McBride, Christopher, Cheruvallath, Zacharia, Komandla, Mallareddy, Tang, Mingnam, Farrell, Pamela, Lawson, J. David, Vanderpool, Darin, Wu, Yiqin, Dougan, Douglas R., Plonowski, Artur, Holub, Corine, and Larson, Chris. Wed .  
"Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2".  United Kingdom.  https://doi.org/10.1016/j.bmcl.2016.04.072.

Copy to clipboard


                    
@article{osti_1358849,

  title        = {Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2},

  author       = {McBride, Christopher and Cheruvallath, Zacharia and Komandla, Mallareddy and Tang, Mingnam and Farrell, Pamela and Lawson, J. David and Vanderpool, Darin and Wu, Yiqin and Dougan, Douglas R. and Plonowski, Artur and Holub, Corine and Larson, Chris},

  abstractNote = {},

  doi          = {10.1016/j.bmcl.2016.04.072},

  journal      = {Bioorganic and Medicinal Chemistry Letters},

  number       = 12,

  volume       = 26,

  place        = {United Kingdom},

  year         = {2016},

  month        = {6}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (Publisher)

Publisher's Version of Record
https://doi.org/10.1016/j.bmcl.2016.04.072

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 14 works

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2
journal, February 2007

Sansen, Stefaan; Yano, Jason K.; Reynald, Rosamund L.
Journal of Biological Chemistry, Vol. 282, Issue 19
DOI: 10.1074/jbc.M611692200

First Suzuki–Miyaura type cross-coupling of ortho-azidobromobenzene with arylboronic acids and its application to the synthesis of fused aromatic indole-heterocycles
journal, October 2007

Pudlo, Marc; Csányi, Dorottya; Moreau, Fabien
Tetrahedron, Vol. 63, Issue 41
DOI: 10.1016/j.tet.2007.07.068

Similar Records in DOE PAGES and OSTI.GOV collections:

Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 1

Journal Article Cheruvallath, Zacharia ; Tang, Mingnam ; McBride, Christopher ; ... - Bioorganic and Medicinal Chemistry Letters
Cited by 10
https://doi.org/10.1016/j.bmcl.2016.04.073
Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Journal Article Lee, Katherine L. ; Ambler, Catherine M. ; Anderson, David R. ; ... - Journal of Medicinal Chemistry

Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays. The medicinal chemistry effort featured the judicious placement of lipophilicity, informed by co-crystal structures with IRAK4 and optimization of ADME properties to deliver clinical candidate PF-06650833 (compound 40). This compound displays a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.
https://doi.org/10.1021/acs.jmedchem.7b00231
Discovery of Potent 2-Aryl-6,7-dihydro-5$$H$$-pyrrolo[1,2-$$a$$]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design

Journal Article Wang, Feng ; Jeon, Kyu Ok ; Salovich, James M. ; ... - Journal of Medicinal Chemistry

WDR5 is a chromatin-regulatory scaffold protein overexpressed in various cancers and a potential epigenetic drug target for the treatment of mixed-lineage leukemia. In this a paper, we describe the discovery of potent and selective WDR5-WINsite inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified several chemically distinct hit series that bind to the WIN site within WDR5. Members of a 6,7-dihydro-5more »« less
Cited by 31
https://doi.org/10.1021/acs.jmedchem.8b00375

Full Text Available
ROLES OF CONFORMATIONAL AND POSITIONAL ADAPTABILITY IN STRUCTURE-BASED DESIGN OF TMC125-R165335 (ETRAVIRINE)AND RELATED NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS THAT ARE HIGHLY POTENT AND EFFECTIVE AGAINST WILD-TYPE AND DRUG-RESISTANT HIV-1 VARIANT

Journal Article DAS, K ; CLARK, A ; LEWI, P ; ... - BIOCHEMISTRY

No abstract prepared.
https://doi.org/10.1021/jm030558s
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

Journal Article Cheng, Hengmiao ; Li, Chunze ; Bailey, Simon ; ... - ACS Medicinal Chemistry Letters
https://doi.org/10.1021/ml300309h

Similar Records

Title: Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design—Part 2

Citation Formats

Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2 journal, February 2007

First Suzuki–Miyaura type cross-coupling of ortho-azidobromobenzene with arylboronic acids and its application to the synthesis of fused aromatic indole-heterocycles journal, October 2007

Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2
journal, February 2007

First Suzuki–Miyaura type cross-coupling of ortho-azidobromobenzene with arylboronic acids and its application to the synthesis of fused aromatic indole-heterocycles
journal, October 2007